The Approved Live-Attenuated Chikungunya Virus Vaccine (IXCHIQ®) Elicits Cross-Neutralizing Antibody Breadth Extending to Multiple Arthritogenic Alphaviruses Similar to the Antibody Breadth Following Natural Infection
Author:
Weber Whitney C.12ORCID, Streblow Zachary J.1, Kreklywich Craig N.1, Denton Michael1, Sulgey Gauthami1ORCID, Streblow Magdalene M.1, Marcano Dorca3ORCID, Flores Paola N.3ORCID, Rodriguez-Santiago Rachel M.3ORCID, Alvarado Luisa I.3, Rivera-Amill Vanessa3ORCID, Messer William B.2, Hochreiter Romana4, Kosulin Karin4ORCID, Dubischar Katrin4, Buerger Vera4ORCID, Streblow Daniel N.15ORCID
Affiliation:
1. Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA 2. Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, OR 97239, USA 3. Ponce Research Institute, Ponce Health Sciences University, Ponce 00716, Puerto Rico 4. Valneva Austria GmbH, 1030 Vienna, Austria 5. Division of Pathobiology and Immunology, Oregon National Primate Research Center, Beaverton, OR 97006, USA
Abstract
The first vaccine against chikungunya virus (CHIKV) was recently licensed in the U.S., Europe, and Canada (brand IXCHIQ®, referred to as VLA1553). Other pathogenic alphaviruses co-circulate with CHIKV and major questions remain regarding the potential of IXCHIQ to confer cross-protection for populations that are exposed to them. Here, we characterized the cross-neutralizing antibody (nAb) responses against heterotypic CHIKV and additional arthritogenic alphaviruses in individuals at one month, six months, and one year post-IXCHIQ vaccination. We characterized nAbs against CHIKV strains LR2006, 181/25, and a 2021 isolate from Tocantins, Brazil, as well as O’nyong-nyong virus (ONNV), Mayaro virus (MAYV), and Ross River virus (RRV). IXCHIQ elicited 100% seroconversion to each virus, with the exception of RRV at 83.3% seroconversion of vaccinees, and cross-neutralizing antibody potency decreased with increasing genetic distance from CHIKV. We compared vaccinee responses to cross-nAbs elicited by natural CHIKV infection in individuals living in the endemic setting of Puerto Rico at 8–9 years post-infection. These data suggest that IXCHIQ efficiently and potently elicits cross-nAb breadth that extends to related alphaviruses in a manner similar to natural CHIKV infection, which may have important implications for individuals that are susceptible to alphavirus co-circulation in regions of potential vaccine rollout.
Funder
Valneva sponsored research agreement to OHSU National Institutes of Health
Reference47 articles.
1. Chikungunya: A decade of burden in the Americas;Ribeiro;Lancet Reg. Health Am.,2024 2. Genetic diversity of Chikungunya virus, India 2006–2010: Evolutionary dynamics and serotype analyses;Sumathy;J. Med. Virol.,2012 3. Broad and long-lasting immune protection against various Chikungunya genotypes demonstrated by participants in a cross-sectional study in a Cambodian rural community;Auerswald;Emerg. Microbes Infect.,2018 4. Tsetsarkin, K.A., Vanlandingham, D.L., McGee, C.E., and Higgs, S. (2007). A single mutation in chikungunya virus affects vector specificity and epidemic potential. PLoS Pathog., 3. 5. Kizu, J.G., Graham, M., Grant, R., McCallum, F., McPherson, B., Auliff, A., Kaminiel, P., and Liu, W. (2023). Prevalence of Barmah Forest Virus, Chikungunya Virus and Ross River Virus Antibodies among Papua New Guinea Military Personnel before 2019. Viruses, 15.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|